Clinical trial NCT04147260: Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin
Official title: Partially-blind, Randomized, Parallel Group, Placebo and Active Comparator-controlled Phase I Clinical Trial to Evaluate the Photosensitivity Potential of BI 730357
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2019-11-01
Enrollment: 85
Sex: ALL
Minimum age (years): 18
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate the photosensitivity potential of BI 730357


Eligibility criteria: Inclusion Criteria:

* Healthy male and female subjects according to the assessment of the Investigator, based on a complete medical history, physical examination (including dermatological skin type assessment), vital signs (blood pressure, pulse rate), 12-lead ECG, and clinical laboratory tests
* 18 to 55 years old
* BMI 18 to 35 kg/m (incl.)
* Fitzpatrick skin type I, II, or III:

  * I Always burns easily, never tans
  * II Always burns easily, tans minimally
  * III Burns moderately, tans gradually
* No ultraviolet exposure of the test areas 4 weeks prior to baseline photo testing
* Normal skin response during preliminary photo testing.
* Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial.
* Women of childbearing potential (WOCBP)1 must be ready and able to use highly effective methods of birth control per ICH M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria is provided in the patient information

Exclusion Criteria:

* Any finding in the medical examination (including blood pressure, pulse rate or ECG) deviating from normal and judged as clinically relevant by the Investigator.
* Any laboratory value outside the reference range that the Investigator considers to be of clinical relevance.
* Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders or any evidence of a concomitant disease judged as clinically relevant by the Investigator.
* Major surgery (major according to the investigator's assessment) performed within 10 weeks prior to randomisation or planned within 2 months after screening.
* Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
* Active skin disorders on the back where photosensitivity testing will be performed.
* Subjects who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
* Subjects not expected to comply with the protocol requirements or not expected to complete the trial as scheduled (e.g. chronic alcohol or drug abuse or any other condition that, in the investigator's opinion, makes the subject an unreliable trial participant).
* Currently enrolled in another investigational device or drug trial, or less than 30 days (or 5 half-lives (whichever longer)) since ending another investigational drug trial.
* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.
* History of relevant allergy or hypersensitivity (including allergy to the trial medication or its excipients).
* History of hypersensitivity to ciprofloxacin, any member of the quinolone class of antibacterials.
* History of hypersensitivity to sunlight or artificial source of intense light, especially UV light.
* Chronic or acute infections which are of relevance in the opinion of the Investigator.
* Positive result for HIV, HBV, and hepatitis C (Hep C) at screening.
* History of TB or positive finding in IGRA.
* Unwillingness/inability to refrain from intake of alcoholic beverages from 48 hours prior to the trial medication administration and until Day 7 post trial medication administration.
* Positive drug screening.
* Blood donation of more than 500 mL within 30 days prior to administration of trial medication or intended donation during the trial.
* Intention to perform excessive physical activities within 4 days prior to administration of trial medication or contact sport during the entire trial and unwilling to avoid vigorous exercise for 7 days post dosing.
* Inability to comply with dietary regimen of trial site.
* Unwillingness to adhere to the rules of UV-light protection
* Received a live vaccination within 12 weeks prior to randomisation (visit 2), or any plan to receive a live vaccination during the conduct of this trial.
* Subjects with known prolongation of the QT interval, risk factors for QT prolongation or torsade de pointes.

Primary outcomes:
measure: Photosensitivity Index at 24 Hours Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At 24 hours after irradiation on Day 8
measure: Photosensitivity Index at 24 Hours Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At 24 hours after irradiation on Day 8
Secondary outcomes:
measure: Photosensitivity Index (PI) at 10 Minutes Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At 10 minutes after irradiation on Day 8
measure: Photosensitivity Index (PI) at 10 Minutes Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At 10 minutes after irradiation on Day 8
measure: Photosensitivity Index (PI) at 1 Hour Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At 1 hour after irradiation on Day 8
measure: Photosensitivity Index (PI) at 1 Hour Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At 1 hour after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 10 Minutes Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At baseline (Day -2) and at 10 minutes after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 10 Minutes Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At baseline (Day -2) and at 10 minutes after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 1 Hour Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At baseline (Day -2) and at 1 hour after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 1 Hour Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At baseline (Day -2) and at 1 hour after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 24 Hours Under Condition 1 (i.e., Under Full Range of UVB/UVA Exposure, Simulating Midday Summer Outdoor Sun Exposure)
timeFrame: At baseline (Day -2) and at 24 hours after irradiation on Day 8
measure: Minimum Erythema Dose (MED) Percent Change From Baseline at 24 Hours Under Condition 2 (i.e., Under UVA Exposure Only, Simulating Indoor Sun Exposure Behind Window Glass)
timeFrame: At baseline and at 24 hours
Other outcomes:
Locations:
city: Fair Lawn
country: United States
facility: TKL Research, Inc.
state: New Jersey
Study officials:
References: